Citadel Advisors LLC cut its holdings in Inflarx NV (NASDAQ:IFRX) by 58.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 79,587 shares of the company’s stock after selling 110,593 shares during the period. Citadel Advisors LLC owned 0.34% of Inflarx worth $2,732,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in IFRX. Matisse Capital acquired a new stake in shares of Inflarx in the third quarter valued at $203,000. Bank of New York Mellon Corp acquired a new stake in shares of Inflarx in the third quarter valued at $277,000. JPMorgan Chase & Co. raised its stake in shares of Inflarx by 29.2% in the third quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock valued at $367,000 after acquiring an additional 2,420 shares in the last quarter. Northern Trust Corp raised its stake in shares of Inflarx by 46.9% in the second quarter. Northern Trust Corp now owns 11,624 shares of the company’s stock valued at $375,000 after acquiring an additional 3,709 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Inflarx by 33.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 16,916 shares of the company’s stock valued at $546,000 after acquiring an additional 4,214 shares in the last quarter. Hedge funds and other institutional investors own 57.12% of the company’s stock.
Several analysts have recently issued reports on IFRX shares. Zacks Investment Research cut Inflarx from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. ValuEngine upgraded Inflarx from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Credit Suisse Group started coverage on Inflarx in a research note on Monday. They issued an “outperform” rating and a $47.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Inflarx has a consensus rating of “Buy” and an average target price of $45.50.
NASDAQ:IFRX opened at $29.51 on Tuesday. Inflarx NV has a 12 month low of $17.50 and a 12 month high of $42.83.
ILLEGAL ACTIVITY WARNING: This story was first reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.fairfieldcurrent.com/news/2018/12/11/inflarx-nv-ifrx-position-reduced-by-citadel-advisors-llc.html.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
See Also: Earnings Reports
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.